|S1949||Menadione||<1 mg/mL||34 mg/mL||34 mg/mL|
|S1857||Etidronate||41 mg/mL||<1 mg/mL||<1 mg/mL|
|S1514||Cyclosporine||<1 mg/mL||100 mg/mL||100 mg/mL|
|S4007||Pentamidine isethionate||100 mg/mL||100 mg/mL||<1 mg/mL|
|S7437||Sal003||<1 mg/mL||93 mg/mL||<1 mg/mL|
|S7639||3PO||<1 mg/mL||42 mg/mL||42 mg/mL|
|S3678||PTP Inhibitor II||<1 mg/mL||45 mg/mL||45 mg/mL|
|S3670||Cefsulodin sodium||100 mg/mL||100 mg/mL||<1 mg/mL|
|S3696||PTP Inhibitor I||<1 mg/mL||43 mg/mL||43 mg/mL|
|S3620||β-Glycerophosphate sodium salt hydrate||61 mg/mL||<1 mg/mL||<1 mg/mL|
|S4013||Sodium Monofluorophosphate||29 mg/mL||<1 mg/mL||<1 mg/mL|
|S7485||CCT007093||<1 mg/mL||1 mg/mL||<1 mg/mL|
|S7537||LB-100||53 mg/mL||<1 mg/mL||<1 mg/mL|
|S7383||(-)-p-Bromotetramisole Oxalate||30 mg/mL||74 mg/mL||<1 mg/mL|
|S8278||SHP099||2 mg/mL||77 mg/mL||<1 mg/mL|
|S7573||GSK2830371||<1 mg/mL||92 mg/mL||92 mg/mL|
|S8182||NSC87877||100 mg/mL||100 mg/mL||<1 mg/mL|
|S8248||IQ-1||<1 mg/mL||72 mg/mL||7 mg/mL|
Menadione(Vitamin K3), a fat-soluble compound, is an inhibitor of Cdc25 phosphatase and mitochondrial DNA polymerase γ (pol γ), used as a nutritional supplement.
Etidronate is a non-aminobisphosphonate, show protein tyrosine phosphatase (PTP) inhibitory activity, used for the treatment of Paget's disease and the prevention of heterotopic ossification.
Cyclosporine is a calcineurin phosphatase pathway inhibitor, used as an immunosuppressant drug to prevent rejection in organ transplantation.
Pentamidine is an inhibitor of PRL Phosphatases and also inhibits synthesis of DNA, RNA and protein.
Sal003 is a potent and cell-permeable eIF-2α phosphatase inhibitor.
3PO is a small-molecule inhibitor of PFKFB3 with an IC50 of 22.9 μM for recombinant human PFKFB3 protein and does not inhibit PFK-1 activity. It suppresses glucose uptake, and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+, and NADH.
PTP Inhibitor II is a cell-permeable protein tyrosine phosphatase (PTP) inhibitor that covalently binds the catalytic domain of the Src homology region 2 domain-containing phosphatase (SHP-1(ΔSH2)) with Ki value of 128 μM.
Cefsulodin is a β-lactam antibiotic and inhibits mPTPB with the IC50 of 16 μM.
PTP Inhibitor I is a cell-permeable, protein tyrosine phosphatase (PTP) inhibitor with Ki values of 43 and 42 μM for SHP-1(ΔSH2) and PTP1B, respectively.
β-Glycerophosphate (sodium salt hydrate) is a potent protein phosphatase inhibitor.
Sodium Monofluorophosphate is a competitive inhibitor of pyruvate kinase and alkaline phosphatase with Ki of 3.4 mM and 69 μM, respectively, which also irreversibly inhibits phosphorylase phosphatase with Ki of 0.5 mM.
CCT007093 is a potent PPM1D (WIP1) inhibitor with IC50 of 8.4 μM.
(A-B)Twenty-four hours after plating 1×105 shh-EGFP cells, media was changed to serum-free media containing vehicle (Vh), DMSO, CCT007093 (CCT, 5µM), and/or Shh (3µg/mL). Cells were also transduced with LentiORF-RFP-CTRL or LentiORF-YFP-WIP1 lentivirus. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI (left-hand panels). Quantification of cells, per high power field (HPF), that express green fluorescent protein (GFP) or Ki-67 (right-hand panels). Bars, mean of cell counts from 10 representative fields for each experimental condition.
LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor with IC50s of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.
LB-100 (a protein phosphatase-2A inhibitor) induces a significant increase for hypoxia-inducible factor (HIF)-1α and vascular endothelial growth factor (VEGF)-C expression by enhancing phosphatidylinositol 3-kinase (PI3K)p85/AKT/ mechanistic target of rapamycin (mTOR) signaling. Western blot analysis results for phosphorylated and total PI3Kp85/AKT/mTOR, HIF-1α, and VEGF-C with or without monocyte chemoattractant protein (MCP)-1 or LB-100 treatment. Bar graphs show quantitative results by densitometric analysis. n = 3 or more independent replications. ∗P < 0.05, ∗∗P < 0.01. Gapdh, glyceraldehyde-3-phosphate dehydrogenase; p, phosphorylated.
(-)-p-Bromotetramisole Oxalate is a potent and non-specific alkaline phosphatase inhibitor.
SHP099 is a highly potent, selective and orally bioavailable small-molecule SHP2 inhibitor with an IC50 value of 0.071 μM and shows no activity against SHP1.
GSK2830371 is an orally active, allosteric Wip1 phosphatase inhibitor with IC50 of 6 nM.
NSC-87877 is a cell-permeable inhibitor of both SHP-1 and SHP-2 with IC50 values of 355 and 318 nM respectively. It also inhibits EGF-induced Erk1/2 activation in HEK293 cells and significantly reduces MDA-MB-468 cell viability/proliferation.
IQ-1 enables Wnt/β-catenin-driven expansion of mouse ESCs and prevents spontaneous differentiation, Maintains embryonic stem cell (ESC) pluripotency in Wnt3a-treated cells and prevents PP2A/Nkd interaction.